Immunovant (NASDAQ: IMVT) shares fiscal Q1 2025 results update

Rhea-AI Filing Summary

Immunovant, Inc. furnished an update on its business by issuing a press release with financial results for its fiscal first quarter ended June 30, 2025. The company reported these results publicly on August 11, 2025, and attached the press release as Exhibit 99.1.

The disclosure is made under the Results of Operations and Financial Condition section and is treated as furnished rather than filed, which limits certain legal liabilities. The report is signed on behalf of Immunovant by Chief Financial Officer Tiago Girao on August 11, 2025.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001764013FALSE00017640132025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

IMMUNOVANT, INC.

(Exact name of Registrant as specified in its Charter)

Delaware						001-38906			83-2771572
(State or other jurisdiction of incorporation or organization)						(Commission File Number)			(IRS Employer Identification No.)
320 West 37th Street
New York,			NY						10018
(Address of principal executive offices)									(Zip Code)

Registrant’s telephone number, including area code: (917) 580-3099

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

IMVT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On August 11, 2025, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal first quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release, dated August 11, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			IMMUNOVANT, INC.
			By:						/s/ Tiago Girao
									Tiago Girao
									Chief Financial Officer
Date: August 11, 2025

FAQ

What did Immunovant (IMVT) announce on August 11, 2025?

On August 11, 2025, Immunovant, Inc. issued a press release announcing its financial results for its fiscal first quarter ended June 30, 2025.

Which reporting period does Immunovant’s latest results cover?

The financial results discussed by Immunovant cover its fiscal first quarter ended June 30, 2025.

What is included as Exhibit 99.1 in Immunovant’s 8-K filing?

Exhibit 99.1 is the press release dated August 11, 2025, in which Immunovant announces its fiscal first-quarter 2025 financial results.

How is the financial information in this Immunovant 8-K treated legally?

The information in Item 2.02, including Exhibit 99.1, is furnished rather than filed, and is not subject to Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Who signed Immunovant’s August 11, 2025 Form 8-K?

The Form 8-K was signed on behalf of Immunovant, Inc. by its Chief Financial Officer, Tiago Girao, dated August 11, 2025.

On which exchange is Immunovant’s common stock listed and under what symbol?

Immunovant’s common stock, with a par value of $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol IMVT.